Table 4.
Properties of the vaccine constructs.
| Properties | V1 | V2 | V3 | V4 | V5 |
|---|---|---|---|---|---|
| adjuvant | 50S ribosomal L7/L12 | Beta-defensin | LT-IIC | Cholera Toxin B subunit | RS09 |
| (CTB) | |||||
| Antigenicity (Vaxijen/ANTIGENpro) | 0.62/0.56 | 0.68/0.60 | 0.64/0.59 | 0.66/0.84 | 0.69/0.59 |
| Allergenicity (AllerTOP v2.0+AlgPred) | NA | NA | NA | NA | NA |
| Toxicity | NT | NT | toxic | toxic | NT |
| Number of amino acids | 511 | 426 | 479 | 484 | 388 |
| Molecular weight (Da) | 56700.70 | 48421.41 | 53920.37 | 54905.58 | 43952.00 |
| Theoretical isoelectric point (pI) | 8.61 | 9.56 | 9.35 | 9.27 | 9.39 |
| The estimated half-life(a) | 30 hours | 30 hours | 30 hours | 30 hours | 30 hours |
| The estimated half-life(b) | >20 hours | >20 hours | >20 hours | >20 hours | >20 hours |
| The estimated half-life(c) | >10 hours | >10 hours | >10 hours | >10 hours | >10 hours |
| The instability index (II) | 30.91 | 36.62 | 34.19 | 35.65 | 35.68 |
| Aliphatic index | 89.06 | 82.25 | 84.15 | 84.52 | 84.05 |
| Grand average of hydropathicity (GRAVY) | -0.051 | -0.19 | -0.13 | -0.171 | -0.127 |
| Solubility | 0.975118 | 0.835770 | 0.610239 | 0.867569 | 0.869869 |
The estimated half-life(a): Estimated half-life of the vaccine in mammalian reticulocytes (in vitro); The estimated half-life(b): Estimated half-life of the vaccine in yeast (in vitro); The estimated half-life(c): Estimated half-life of the vaccine in Escherichia coli (in vivo).
NA, Non-allergenic; NT, Non-toxic.